u The earnings figures in the Aug. 8 issue of BioWorld Today misstatedsecond quarter results for Procept Inc. The company had revenues of$1.62 million, a 259 percent increase over the comparable 1993quarter. The net loss was $2.04 million (32 cents) compared to $2.16million (54 cents). Research and development expenses were $2.73million, a 39 percent increase. The company had $19.13 million in cashand equivalents and 6.35 million shares outstanding.u Also, Regeneron Pharmaceuticals Inc. said it has a new accountingmethod that no longer includes long-term investments in thecash/equivalents column. To be compared accurately to last year'sposition, $18.2 million should be added to the $52.2 million.
(c) 1997 American Health Consultants. All rights reserved.